MetLife Investment Management’s Rubius Therapeutics, Inc RUBY Stock Holding History

MetLife Investment Management’s Portfolio RUBY Stock Details RUBY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-18,852	Closed	-$104K	–	2933
2022 Q1	$104K	Buy	18,852 +2,096	+13%	+$13.3K	﹤0.01%	2617
2021 Q4	$162K	Hold	16,756	–	–	﹤0.01%	2183
2021 Q3	$300K	Hold	16,756	–	–	﹤0.01%	1822
2021 Q2	$409K	Buy	16,756 +2,464	+17%	+$61.6K	﹤0.01%	1694
2021 Q1	$379K	Buy	+14,292	New	+$209K	﹤0.01%	1680
2020 Q3	–	Sell	-17,589	Closed	-$105K	–	2344
2020 Q2	$105K	Buy	+17,589	New	+$104K	﹤0.01%	2233
2020 Q1	–	Sell	-16,410	Closed	-$156K	–	2321
2019 Q4	$156K	Hold	16,410	–	–	﹤0.01%	2113
2019 Q3	$129K	Hold	16,410	–	–	﹤0.01%	2194
2019 Q2	$258K	Hold	16,410	–	–	﹤0.01%	1881
2019 Q1	$297K	Buy	16,410 +5,629	+52%	+$86.4K	﹤0.01%	1758
2018 Q4	$173K	Hold	10,781	–	–	﹤0.01%	1985
2018 Q3	$259K	Buy	+10,781	New	+$246K	﹤0.01%	1944

Other funds holding RUBY

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AFM

Abbot Financial Management Andover, Massachusetts $293M AUM 36.12% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MetLife Investment Management's RUBY Position: Q2 2022 in Review

MetLife Investment Management sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2022, closing a stake of 18,852 shares — an estimated $104K sold.

MetLife Investment Management first reported a position in RUBY in Q3 2018 and held it in 12 quarters. The position peaked at $409K in Q2 2021. 72 funds tracked by Wall St. Rank hold RUBY as of Q2 2022.

MetLife Investment Management reported no remaining Rubius Therapeutics, Inc position as of Q2 2022 after selling out during the quarter.
MetLife Investment Management sold 18,852 Rubius Therapeutics, Inc shares in Q2 2022, an estimated $104K.
MetLife Investment Management first reported a position in Rubius Therapeutics, Inc in Q3 2018 and held it in 12 quarters.
MetLife Investment Management's Rubius Therapeutics, Inc position peaked at $409K in Q2 2021.
72 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2022.

Based on MetLife Investment Management's 13F filing for Q2 2022, filed 11 Aug 2022.